# Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct06606730/  
OnCo record `nct06606730` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of pembrolizumab in triple-negative breast cancer, run by UNICANCER, now recruiting.

## Summary

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer is a phase 3, randomised interventional study registered as NCT06606730 by UNICANCER, with a registry enrolment figure of 2454 participants, started 2025-07-23 and due to reach its primary completion in 2033-01-01. Interventions recorded: Pembrolizumab; Deescalation. Conditions listed: Breast Cancers; Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Estrogen receptor (ER) and Progesterone receptor (PR) ≤10%; HER2-negative as per ASCO/CAP guidelines Note: In case of bilateral breast cancer, participation in the study is permitted as long as both tumours are triple negative;". Sites: Belgium, France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: OPT-PEMBRO
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06606730
- Phase: 3
- Setting: OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab
- Sponsor: UNICANCER
- Enrolled: 2454

## Sources

- ClinicalTrials.gov NCT06606730: https://clinicaltrials.gov/study/NCT06606730

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06606730.json